VBI's vaccine offers higher seroprotection rates and five to eight times higher antibody geometric mean concentration regardless of body mass index, diabetes status, and age. No safety issues were observed.

The vaccine is composed of the spike, pre-S1, and pre-S2 surface antigens of the hepatitis B virus and is approved for use and commercially available in Israel. The company has previously filed regulatory submissions for the vaccine candidate in the U.S. and Europe in November 2020 and is in the process of filing submissions for Canada and the U.K.

Approximately 1,600 adults participated in the study, which was published in the Lancet Infectious Diseases.

VBI touts positive preclinical COVID-19 vaccine data
Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle technology from VBI Vaccines (VBI).

CEPI, VBI to develop COVID-19 vaccine against variants
The Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of enveloped viruslike particle vaccine candidates against SARS-CoV-2...

FDA accepts VBI's hepatitis B vaccine BLA
The U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) submitted by VBI Vaccines for its 3-antigen prophylactic...

VBI provides COVID-19 vaccine updates amid supply chain delays
VBI Vaccines has provided preclinical updates on its two COVID-19 vaccine programs: VBI-2901, a trivalent pan-coronavirus vaccine candidate, and VBI-2902,...

VBI Vaccines move two COVID-19 vaccines to clinical trials
VBI Vaccines said that it has selected two of its COVID-19 vaccine candidates to proceed to a phase I/II clinical study expected to begin around the end...